Cargando…
A drug‐disease model for predicting survival in an Ebola outbreak
REGN‐EB3 (Inmazeb) is a cocktail of three human monoclonal antibodies approved for treatment of Ebola infection. This paper describes development of a mathematical model linking REGN‐EB3’s inhibition of Ebola virus to survival in a non‐human primate (NHP) model, and translational scaling to predict...
Autores principales: | Toroghi, Masood Khaksar, Al‐Huniti, Nidal, Davis, John D., DiCioccio, A. Thomas, Rippley, Ronda, Baum, Alina, Kyratsous, Christos A., Sivapalasingam, Sumathi, Kantrowitz, Joel, Kamal, Mohamed A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579403/ https://www.ncbi.nlm.nih.gov/pubmed/35895082 http://dx.doi.org/10.1111/cts.13383 |
Ejemplares similares
-
Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies
por: Yang, Feng, et al.
Publicado: (2021) -
A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglycerides receiving evinacumab
por: Khaksar Toroghi, Masood, et al.
Publicado: (2021) -
Base and Covariate Population Pharmacokinetic Analyses of Dupilumab in Adolescents and Children ≥6 to <12 Years of Age Using Phase 3 Data
por: Kovalenko, Pavel, et al.
Publicado: (2021) -
Base and Covariate Population Pharmacokinetic Analyses of Dupilumab Using Phase 3 Data
por: Kovalenko, Pavel, et al.
Publicado: (2020) -
Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis
por: Kovalenko, Pavel, et al.
Publicado: (2020)